Replies to post #204862 on Biotech Values

[DewDiligence]

Endurance-3 seems to be missing—perhaps a late-breaker?

That's my hope; ENDURANCE-3 is going to be one of the most consequential trials (due to the Sovaldi/Dakilza active-control arm) for ABBV/ENTA's next-gen regimen.

who in marketing invented those names - glecaprevir (ABT-493) / pibrentasvir (ABT-530)?

At least they have the proper suffixes: "previr" for a PI, and "asvir" for an NS5A :- )